Corbus Pharmaceuticals (CRBP) shares slumped 10% in recent trading Friday despite reporting what it described as encouraging data from the "Western" clinical trial of its CRB-701 anti-body drug conjugate.

A total of 26 patients with metastatic urothelial cancer and other solid tumors associated with Nectin-4 expression were evaluable at December 2024 data cut point in the US and UK study.

The phase 1 Western dose escalation study's results mirrored those from the China study in terms of safety, tolerability, and pharmacokinetics, the company said. No dose-limiting adverse events were reported from both studies, it said.

However, Corbus reported one response in four metastatic urothelial cancer patients dosed in the Western study, compared with the China study's 44% involving nine patients.

The company on Friday presented the data from the Western study at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Price: 8.53, Change: -0.95, Percent Change: -10.02